| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 19, 2004
From the Department of Cardiology (K.S., E.A., S.K., P.I., A.M., V.V., G.P., D.K., D.V.C.), Onassis Cardiac Surgery Centre, Athens, Greece; the Biostatistics Unit and Nutrition Epidemiology Group (D.C.G.), University of Leeds, Leeds, UK; and the Division of Cardiology (C.E.B.), University of British Columbia, Vancouver, Canada. * To whom correspondence should be addressed. E-mail: spargias{at}ocsc.gr.
Background--Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated. Methods and Results--We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration Conclusions--Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.
Revised on June 30, 2004
Accepted on July 1, 2004
Ascorbic Acid Prevents Contrast-Mediated Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention
Konstantinos Spargias MD*,
1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine
0.5 mg/dL or a relative increase of
25% measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95% CI, 0.00 to 0.17; P=0.049).
Related Article:
Circulation 2004 110: 2773.
This article has been cited by other articles:
![]() |
K. Spargias, E. Adreanides, E. Demerouti, A. Gkouziouta, A. Manginas, G. Pavlides, V. Voudris, and D. V. Cokkinos Iloprost Prevents Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention Circulation, November 3, 2009; 120(18): 1793 - 1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kim, Y. M. Seok, K.-J. Jung, and K. M. Park Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice Am J Physiol Renal Physiol, August 1, 2009; 297(2): F461 - F470. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sendeski, A. Patzak, T. L. Pallone, C. Cao, A. E. Persson, and P. B. Persson Iodixanol, Constriction of Medullary Descending Vasa Recta, and Risk for Contrast Medium-induced Nephropathy Radiology, June 1, 2009; 251(3): 697 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lameire, W. van Biesen, E. Hoste, and R. Vanholder The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury NDT Plus, February 1, 2009; 2(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Goldfarb, P. A. McCullough, J. McDermott, and S. B. Gay Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional Cardiology Mayo Clin. Proc., February 1, 2009; 84(2): 170 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Romano, C. Briguori, C. Quintavalle, C. Zanca, N. V. Rivera, A. Colombo, and G. Condorelli Contrast agents and renal cell apoptosis Eur. Heart J., October 2, 2008; 29(20): 2569 - 2576. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Brar, A. Y.-J. Shen, M. B. Jorgensen, A. Kotlewski, V. J. Aharonian, N. Desai, M. Ree, A. I. Shah, and R. J. Burchette Sodium Bicarbonate vs Sodium Chloride for the Prevention of Contrast Medium-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Randomized Trial JAMA, September 3, 2008; 300(9): 1038 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maioli, A. Toso, M. Leoncini, M. Gallopin, D. Tedeschi, C. Micheletti, and F. Bellandi Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention J. Am. Coll. Cardiol., August 19, 2008; 52(8): 599 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. McCullough Contrast-Induced Acute Kidney Injury J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1419 - 1428. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Toprak, M. Cirit, M. Tanrisev, C. Yazici, O. Canoz, M. Sipahioglu, A. Uzum, R. Ersoy, and E. Y. Sozmen Preventive effect of nebivolol on contrast-induced nephropathy in rats Nephrol. Dial. Transplant., March 1, 2008; 23(3): 853 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Kelly, B. Dwamena, P. Cronin, S. J. Bernstein, and R. C. Carlos Meta-analysis: Effectiveness of Drugs for Preventing Contrast-Induced Nephropathy Ann Intern Med, February 19, 2008; 148(4): 284 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. T. C. Wong and M. G. Irwin Contrast-induced nephropathy Br. J. Anaesth., October 1, 2007; 99(4): 474 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Solomon Contrast media nephropathy--how to diagnose and how to prevent? Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1812 - 1815. [Full Text] [PDF] |
||||
![]() |
C. Briguori, F. Airoldi, D. D'Andrea, E. Bonizzoni, N. Morici, A. Focaccio, I. Michev, M. Montorfano, M. Carlino, J. Cosgrave, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies Circulation, March 13, 2007; 115(10): 1211 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker Medical Care of Kidney Transplant Recipients after the First Posttransplant Year Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network Prophylaxis Strategies for Contrast-Induced Nephropathy JAMA, June 21, 2006; 295(23): 2765 - 2779. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tepel, P. Aspelin, and N. Lameire Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach Circulation, April 11, 2006; 113(14): 1799 - 1806. [Full Text] [PDF] |
||||
![]() |
B. J. Barrett and P. S. Parfrey Preventing Nephropathy Induced by Contrast Medium N. Engl. J. Med., January 26, 2006; 354(4): 379 - 386. [Full Text] [PDF] |
||||
![]() |
Other articles noted Evid. Based Med., August 1, 2005; 10(4): 127 - 128. [Full Text] [PDF] |
||||
![]() |
I. Goldenberg and S. Matetzky Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies Can. Med. Assoc. J., May 24, 2005; 172(11): 1461 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |